

FINAL PROJECT REPORT

Date: May 2011

Name:

Lisa Stamp

Project Title:

Effects of frusemide on uric acid and oxypurinol in patients with gout.

Please copy the "Specific Objective(s)" statement, entered on your application form, in the space below.

- 1) To determine the extent to which short-term treatment with allopurinol and frusemide increase serum uric acid and plasma oxypurinol concentrations in patients with gout.
- 2) To determine the extent to which long-term treatment with allopurinol and frusemide results in increased serum uric acid and increased plasma oxypurinol concentrations.

Briefly describe how successful you were in achieving the stated objective(s). If the objective(s) was not achieved, explain why that is the case and describe what you did manage to achieve.

All objectives have been met.

1) To determine the extent to which short-term treatment with allopurinol and frusemide increase serum uric acid and plasma oxypurinol concentrations in patients with gout. We have completed the recruitment for this objective. All of the laboratory assays have been completed. Data analysis will commence in the near future and it is anticipated this will take 2-3 months. Additional complex pharmacokinetic modelling will be undertaken with Professor Stephen Duffell, Pharmacology Department, University of Otago, Dunedin in the future.

2) To determine the extent to which long-term treatment with allopurinol and frusemide results in increased serum uric acid and increased plasma oxypurinol concentrations. Recruitment for this objective proved more challenging, mainly due to the requirement for matching on CrCL. However, we have managed to complete recruitment for this objective. All laboratory data is now complete and data analysis is currently underway. It is expected to take 2-3 months to complete the data analysis.

It is anticipated that results from objective 2 will be presented at the NZ Rheumatology Association meeting in August 2011. In addition an abstract will be submitted to the American College of Rheumatology Annual Scientific Meeting in October 2011. A manuscript regarding this work is currently in preparation. Data from objective one will be presented in due course when the analysis is completed.

Briefly describe any interesting outcomes which might not have been considered in your original objectives (if any).

Data analysis underway so unknown at present.